A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147 on ClinicalTrials.gov · last registry update 2024-04-24

Stopped early, having planned 14 participants. The sponsor logged completion for 18 September 2023. Primary outcome, as filed: Change in ICP From Baseline to Week 24 Measured by Lumbar Puncture (LP), Where a Higher LP Value Indicates Greater ICP. exenatide is approved in the US, but not for hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Invex Therapeutics Ltd.
Sponsor type: Industry
Enrollment: 14
Started: 2022-11-18
Primary completion: 2023-09-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in ICP From Baseline to Week 24 Measured by Lumbar Puncture (LP), Where a Higher LP Value Indicates Greater ICP

Conditions studied

Idiopathic Intracranial Hypertension

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.